metaEvidence - overview


			DCR
mHNSCC - L2 - all population metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - all population
versus Standard of Care (SoC)
	durvalumab alone vs. Standard of Care (SoC)	1	1.00 [0.63; 1.58], 1 RCT, I2=0% inconclusive result
	durvalumab plus tremelimumab vs. Standard of Care (SoC)	1	1.12 [0.72; 1.75], 1 RCT, I2=0% inconclusive result
	nivolumab alone vs. Standard of Care (SoC)	1	-
	pembrolizumab alone vs. Standard of Care (SoC)	1	-